Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Precision Assays
Seattle, Washington, USA
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Precision Assays developed a large portfolio of validated multiplex, immuno-MRM protein assays for quantitative analysis in immuno-oncology; their platform’s clinical proof of concept and CPTAC characterization enabled clinical protein biomarker quantification for therapeutic development. The company’s assay panels are now integrated into CellCarta’s offerings, supporting exploratory to clinical endpoints in precision oncology and biomarker studies
- Therapeutic areas
- Oncology
- Modalities
- ProteinMultiplex protein assay
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
CellCartaFred Hutchinson Cancer Center
Beyond the preview
Go deeper on Precision Assays.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precision Assays.